Investor Relations
Press Releases
[+view all]
08.29.2024
ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split
08.26.2024
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connectionwith the Proposed Merger with Oruka Therapeutics
08.23.2024
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
Investor Relations
Press Releases
[+view all]
08.29.2024
ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split
08.26.2024
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connectionwith the Proposed Merger with Oruka Therapeutics
08.23.2024
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
Presentations
[GO]
Annual Financial Reports
[GO]
SEC Filings
[GO]
Frequently Asked Questions
[GO]
Corporate Governance
Committee Charters
Audit Committee
Compensation Committee
Nominating & Governance Committee
Governance Documents
Board of Directors Corporate Governance Principles
ARCA biopharma, Inc. Code of Business Conduct and Ethics
ARCA biopharma, Inc. Complaint and Investigation Policy and Procedure
Contact the Board
Chairperson
Member
Audit Committee
Compensation Committee
Nominating & Governance Committee
James Flynn
Linda Grais, M.D.
Robert E. Conway
Anders Hove, M.D.